1. Home
  2. CZNC vs VOGX Comparison

CZNC vs VOGX Comparison

Compare CZNC & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

N/A

Current Price

$25.74

Market Cap

465.4M

Sector

Finance

ML Signal

N/A

VOGX

Vogenx Inc Common Stock

N/A

Current Price

$29.80

Market Cap

456.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CZNC
VOGX
Founded
1864
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.4M
456.5M
IPO Year
2009
2026

Fundamental Metrics

Financial Performance
Metric
CZNC
VOGX
Price
$25.74
$29.80
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$23.50
N/A
AVG Volume (30 Days)
59.8K
212.4K
Earning Date
05-12-2026
N/A
Dividend Yield
4.87%
N/A
EPS Growth
N/A
N/A
EPS
0.81
N/A
Revenue
N/A
N/A
Revenue This Year
$3.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.87
$14.80
52 Week High
$26.26
$35.50

Technical Indicators

Market Signals
Indicator
CZNC
VOGX
Relative Strength Index (RSI) 54.09 81.95
Support Level $25.00 $27.37
Resistance Level $26.12 $35.06
Average True Range (ATR) 0.46 4.37
MACD -0.07 -0.15
Stochastic Oscillator 51.20 67.31

Price Performance

Historical Comparison
CZNC
VOGX

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About VOGX Vogenx Inc Common Stock

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Share on Social Networks: